Probenecid inhibits cisplatin (CP) secretion in humans and protects against CP‐induced nephrotoxicity in rats. The authors conducted a Phase I trial of escalating doses of CP using probenecid as a chemoprotector. Fifty‐four courses of CP at doses ranging from 100 to 160 mg/m2 were given by 24‐hour infusion to 36 patients. There was no renal impairment at any dose. Ototoxicity, however, became the dose‐limiting toxicity; 14 patients experienced a 20 or greater decibel (dB) loss. Seven percent of courses were associated with a leukocyte count of less than 1.5 × 10/μ1, and 19% with a platelet count of less than 50 × 103/μ1. Only three patients developed neurotoxicity. Correlating pharmacokinetic data and toxicity, the authors found that high cumulative dose, area under the curve (AUC) for unbound platinum, and cumulative AUC were associated with ototoxicity and peripheral neuropathy. It was concluded that probenecid may protect against CP nephrotoxicity and warrants further investigation. Its unique mechanism of action and lack of toxicity make it ideal to combine with other chemoprotectors.
|Original language||English (US)|
|Number of pages||7|
|State||Published - Mar 15 1991|
ASJC Scopus subject areas
- Cancer Research